(secondQuint)Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes.

 The study design is a double blind placebo controlled trial that will enroll subjects between the ages of 8 - 30 who have had the diagnosis of Type 1 diabetes made 4 - 12 months prior to enrollment.

 A single 14 course of treatment with mAb hOKT3gamma1(Ala-Ala), Teplizumab will be given.

 The primary endpoint is the C-peptide response to a mixed meal at 12 months.

 A total of 60 subjects will be enrolled (30 in the drug treatment and 30 in the placebo groups) at 4 study sites: Yale University,the University of California at San Francisco, Children's Hospital of Philadelphia, and the Barbara Davis Diabetes Center.

.

 Anti-CD3 mAb Treatment of Recent Onset Type 1 Diabetes@highlight

This is a randomized placebo controlled study to test whether a single 14 course of treatment with the anti-CD3 monoclonal antibody, hOKT3gamma1(Ala-Ala),Teplizumab will prevent the loss of insulin secretory capacity in individuals with Type 1 diabetes of 4 - 12 months duration since diagnosis.

